According to the study, the results of which were presented at the annual scientific conference of the American College of Allergy, Asthma and Immunology (American College of Allergy, Asthma & Immunology), of patients who had adverse drug reactions in the past or people with a history of atopy, including bronchial asthma, eczema or allergic rhinitis, may be a group at increased risk for developing more severe side effects (NLR).

Physicians are advised to be more vigilant when prescribing new drugs to these patients. Adverse drug reactions are very common, but at the moment it cannot be said that there are many studies that have studied the severity of these reactions, especially those that are allergic or immunological in nature and manifest by rash, hives, angioedema or other skin types. reactions.

To assess the risk factors associated with the severity of the undesirable RLL, a retrospective analysis of 369 adverse drug reactions recorded in hospitalized patients over a period of 13 months (from May 1, 2011 to May 31, 2012) was performed. The reactions were classified as mild (not requiring treatment), significant (treatment was necessary, but stopped without consequences), severe (longer stay in hospital, but without development of persistent disability), disabling ( persistent or life-threatening disability) and fatal.

A total of 51 mild NLRs (13.8%), 140 severe NLRs (37.9%), 148 significant NLRs (40.1%) and 2 disabling NLRs (0.5%) were recorded.

Researchers found that NLR was more common in patients before hospitalization (61.8%) and these reactions were more severe compared to NLR developed in patients during hospitalization (odds ratio 1.47, interval 95% confidence (CI) 0.96-2.24).

60 NLRs were allergic in nature, and the most common drugs responsible for NLRs were radio-opaque substances (in 21% of cases) and fluoroquinolones (in 12% of cases). Slightly more often, allergic NLR occurred in women (53.3%), and the average age of the patients was 55.3 years.

In patients with an atopic history, the probability of developing severe NLR was almost 5 times higher (OR 4.74, 95% CI 0.54-41.4).

In patients who previously reported NLR, the probability of developing severe NLR was 16% higher (RR 1.16, 95% CI 0.4-3.2).

According to previous studies, the risk factors for developing severe NLR are female, preceding allergic reactions to drugs and using multiple drugs at the same time. At the same time, according to previous studies, atopy has not been identified as a risk factor for the development of NLR, in general, and severe NLR, in particular.